EBOV VP40

EBOV VP40 Full Name

Zaire Ebola Virus VP40

EBOV VP40 Introduction

The Ebola virus VP40 protein is the most abundant structural protein in the Ebola virion and serves as the principal matrix protein that drives virus assembly and budding from infected cells. VP40 is a 326-amino-acid protein with a molecular weight of approximately 40 kDa, and it plays a central role in coordinating the late stages of the viral life cycle. Structurally, VP40 adopts a unique rectangular shape composed of two structurally similar domains—an N-terminal domain and a C-terminal domain—connected by a flexible linker region. The N-terminal domain contains hydrophobic residues that mediate membrane association, while the C-terminal domain is involved in oligomerization and lipid raft targeting. VP40 exists in multiple conformational states that are essential for its distinct functions: a monomeric dimer in the cytoplasm, a hexameric ring structure that forms at the plasma membrane to facilitate budding, and an octameric ring that binds RNA and may play a regulatory role in transcription. The structural plasticity of VP40 is remarkable, as the transition between these oligomeric states is triggered by different cellular environments and binding partners, including specific lipid compositions of the plasma membrane. VP40 is both necessary and sufficient for the formation and release of filamentous virus-like particles (VLPs) from mammalian cells, demonstrating that it harbors all the essential information required for efficient virion budding. This property has been widely exploited in the production of EBOV VLPs for vaccine and research applications. The protein localizes predominantly to the inner leaflet of the plasma membrane, where it recruits additional viral components and interacts with the host endosomal sorting complexes required for transport (ESCRT) machinery.

Figure 1. P300-mediated NEDD4 acetylation drives ebolavirus VP40 egress by enhancing NEDD4 ligase activity.

VP40 orchestrates virus assembly and budding through a series of precisely coordinated molecular interactions with both viral and host cell components. The budding process is initiated when VP40 dimers are recruited to the plasma membrane through electrostatic interactions between the C-terminal domain and phosphatidylserine and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) in the inner leaflet. Membrane binding induces a conformational rearrangement that promotes VP40 oligomerization into hexameric structures, which then assemble into two-dimensional lattices underlying the plasma membrane, providing the structural scaffold for the filamentous virion morphology. VP40 interacts directly with the host ESCRT (endosomal sorting complexes required for transport) machinery through late (L) domain motifs in its N-terminal region, specifically the PTAP and PPxY motifs. The PTAP motif engages TSG101 (a component of ESCRT-I), while the PPxY motif interacts with Nedd4-family ubiquitin ligases, and both interactions are essential for efficient membrane scission and particle release. VP40 also mediates interactions with other viral proteins during assembly, including the glycoprotein GP and the nucleoprotein NP, ensuring proper incorporation of all structural components into budding virions. In terms of immune modulation, VP40 has been shown to suppress host immune responses through multiple mechanisms, including the inhibition of interferon signaling by sequestering host factors and the modulation of host cell gene expression. VP40 can also suppress mRNA translation and alter host cell lipid metabolism to facilitate efficient budding. Recent studies have demonstrated that VP40 interacts with the host protein Sec61 translocon to suppress immune gene expression, adding another layer to its immune evasion repertoire. The multifunctional nature of VP40 in both assembly and host modulation underscores its central importance in Ebola virus biology.

VP40 represents a compelling therapeutic target for anti-Ebola drug development due to its essential and multifaceted roles in virus assembly, budding, and immune evasion. Disrupting VP40 function would prevent the formation and release of infectious virions, effectively blocking viral spread within the host. Several therapeutic strategies targeting VP40 have been investigated, including small molecules that interfere with VP40 oligomerization, peptides that disrupt VP40-membrane interactions, and compounds that block VP40-ESCRT engagement. Notably, high-throughput screening has identified small molecules that bind to VP40 and inhibit its ability to form hexameric lattices, thereby preventing VLP production and virus budding. Structural studies of VP40 in various oligomeric states have provided detailed blueprints for rational drug design, revealing druggable pockets at domain interfaces that are critical for conformational transitions. From a vaccine perspective, VP40-based VLPs remain one of the most promising platforms for EBOV vaccine development, as they provide a safe and immunogenic particle that faithfully mimics native virion morphology. The ability of VP40 to drive efficient particle release without any other viral components has been leveraged to create chimeric VLPs displaying GP variants from multiple Ebola virus species, enabling the development of broadly protective filovirus vaccines. In the diagnostic arena, VP40 is a key target antigen for the detection of Ebola virus in patient samples, and its conservation across EBOV variants makes it a reliable marker for diagnostic assays. As drug resistance to polymerase inhibitors and monoclonal antibody therapies remains a concern, targeting VP40 offers a complementary therapeutic approach that could be used in combination regimens to achieve more robust and durable clinical outcomes for patients with Ebola virus disease.

Alternate Names for EBOV VP40

EOBV VP40; Zaire ebolavirus polymerase cofactor VP40; EOBV; Zaire ebolavirus; Zaire Ebola Virus VP40; Ebola Virus; VP40; ebolavirus

• 1. Bornholdt ZA et al. Structural basis for filovirus matrix assembly and budding: crystal structure of Ebola VP40. Protein Sci. 2013;22(4):423-432.
  2. Pavadai E et al. Deep learning-guided discovery of Ebola virus VP40 inhibitors. J Chem Inf Model. 2021;61(9):4384-4395.
  3. Adu-Gyamfi E et al. A loop region in the N-terminal domain of Ebola virus VP40 is important for late domain function and virus-like particle budding. J Biol Chem. 2015;290(4):2346-2355.
  4. Han Z et al. Small molecule probes targeting Ebola virus VP40 reveal a novel host interaction pathway essential for viral egress. PLoS Pathog. 2020;16(7):e1008620.
  5. Zhang et al. P300-mediated NEDD4 acetylation drives ebolavirus VP40 egress by enhancing NEDD4 ligase activity. PLoS Pathogens. 2021. doi: 10.1371/journal.ppat.1009616